Calidi Biotherapeutics Q4 2025 Earnings Narrowed Loss Surprises Stock Declines FITBM Q1 2026 Earnings Strong EPS Surprise of 3509 Outperforms Estimates 4D Molecular Therapeutics FDMT Q1 2026 Earnings NarrowerthanExpected Loss Lifts Shares STWD Q1 2026 Earnings EPS Misses Estimates Amid Challenging CRE Environment CVEO Q1 2026 Earnings EPS Surprise of 45 Despite Negative Earnings NRX Pharmaceuticals Q1 2026 Earnings EPS Miss Marks 114 Surprise Shortfall Stock Surges 20